These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3539901)

  • 21. Antimicrobial activity and stability to beta-lactamase of BMY-28271, a new oral cephalosporin ester.
    Matsui H; Hiraoka M; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1990 Apr; 34(4):555-61. PubMed ID: 2344162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro activity of cefepime against nosocomial isolates.
    Sofianou D; Tsoulfa S; Kontodimou L; Polydorou F; Malaka E
    J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.
    Fung-Tomc J; Huczko E; Pearce M; Kessler RE
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1443-5. PubMed ID: 3143306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.
    Phelps DJ; Carlton DD; Farrell CA; Kessler RE
    Antimicrob Agents Chemother; 1986 May; 29(5):845-8. PubMed ID: 3524432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxime.
    Hiraoka M; Masuyoshi S; Mitsuhashi S; Tomatsu K; Inoue M
    J Antibiot (Tokyo); 1988 Jan; 41(1):86-93. PubMed ID: 3279015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of BMY-28142, a new cephalosporin.
    Norden CW; Neiderriter K
    Chemotherapy; 1987; 33(1):15-7. PubMed ID: 3103990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefepime: a new fourth-generation cephalosporin.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
    Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime.
    Jones RN; Fuchs PC
    J Antimicrob Chemother; 1989 Jan; 23(1):163-5. PubMed ID: 2663806
    [No Abstract]   [Full Text] [Related]  

  • 30. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.
    Bell JM; Turnidge JD;
    Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial and pharmacokinetic properties of M14659, a new injectable semisynthetic cephalosporin.
    Mochizuki H; Oikawa Y; Yamada H; Kusakabe S; Shiihara T; Murakami K; Kato K; Ishiguro J; Kosuzume H
    J Antibiot (Tokyo); 1988 Mar; 41(3):377-91. PubMed ID: 3130365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro activity of cefepime and other antimicrobials: survey of European isolates.
    Thornsberry C; Brown SD; Yee YC; Bouchillon SK; Marler JK; Rich T
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():31-53. PubMed ID: 8150766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics.
    Clarke AM; Zemcov SJ; Wright JM
    J Antimicrob Chemother; 1985 Mar; 15(3):305-10. PubMed ID: 3838981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin.
    Toyosawa T; Miyazaki S; Tsuji A; Yamaguchi K; Goto S
    Antimicrob Agents Chemother; 1993 Jan; 37(1):60-6. PubMed ID: 8431019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin.
    Tomatsu K; Ando S; Masuyoshi S; Kondo S; Hirano M; Miyaki T; Kawaguchi H
    J Antibiot (Tokyo); 1987 Aug; 40(8):1175-83. PubMed ID: 3500158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of HR 810, a new broad-spectrum cephalosporin.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1983 Aug; 2(4):345-9. PubMed ID: 6313358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia.
    Edelstein H; Chirurgi V; Oster S; Karp R; Cassano K; Aiken S; McCabe R
    J Antimicrob Chemother; 1991 Oct; 28(4):569-75. PubMed ID: 1761451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Wakai Y; Kamimura T; Tawara S; Matsumoto S; Matsumoto F; Kuwahara S
    J Antibiot (Tokyo); 1993 Jan; 46(1):88-98. PubMed ID: 8436563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.